Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study
Department of Oncology, Faculty of Medicine and Health, Örebro University Hospital, Örebro, Sweden.
Nordic Market Access AB, Stockholm, Sweden.
Parexel International, Stockholm, Sweden.
Parexel International, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Visa övriga samt affilieringar
2022 (Engelska)Ingår i: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 127, nr 4, s. 720-725Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Breast cancer is the most common cancer among women in Sweden. Whereas survival for the overall breast cancer population is well-documented, survival of patients with metastatic breast cancer (MBC) is harder to quantify due to the lack of reliable data on disease recurrence in national cancer registers. Methods: This study used machine learning to classify the total MBC population in Sweden diagnosed between 2009 and 2016 using national registers, with the aim to estimate overall survival (OS). Results: The total population consisted of 13,832 patients—2528 (18.3%) had de novo MBC whereas 11,304 (81.7%) were classed as having a recurrent MBC. Median OS for patients with MBC was found to be 29.8 months 95% confidence interval (CI) [28.9, 30.6]. Hormone-receptor (HR)-positive MBC had a median OS of 37.0 months 95% CI [35.9, 38.3] compared to 9.9 months 95% CI [9.1, 11.0] for patients with HR-negative MBC. Conclusion: This study covered the entire MBC population in Sweden during the study time and may serve as a baseline for assessing the effect of new treatment strategies in MBC introduced after the study period.

Ort, förlag, år, upplaga, sidor
Springer Nature, 2022. Vol. 127, nr 4, s. 720-725
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:umu:diva-203223DOI: 10.1038/s41416-022-01845-zISI: 000799700200002PubMedID: 35597870Scopus ID: 2-s2.0-85130306404OAI: oai:DiVA.org:umu-203223DiVA, id: diva2:1728131
Tillgänglig från: 2023-01-17 Skapad: 2023-01-17 Senast uppdaterad: 2023-05-24Bibliografiskt granskad

Open Access i DiVA

fulltext(736 kB)77 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 736 kBChecksumma SHA-512
7d49563ca4d1fab3f787f16515cfa68e62623914df471ad62a1a83c764e188edab7a06a4080783585bbc55be6f06eee78a2b33b74273e88f8d83b18564c99890
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Freilich, Jonatan

Sök vidare i DiVA

Av författaren/redaktören
Freilich, Jonatan
Av organisationen
Avdelningen för medicin
I samma tidskrift
British Journal of Cancer
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 79 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 219 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf